Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...

Senescence. It’s a beautiful-sounding word whose tones suggest it should be a perfume or an essential oil. But that’s not ...

UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...

Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

Engitix plans to use the funds for preclinical development across its pipeline in solid tumors and fibrosis, and to expand ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...

A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together produces a much stronger effect than using either one alone, suggesting a ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.

New human clinical trial proves arginine, an amino acid, can modify plaque formation on teeth, thereby protecting ...

Detecting cancer in the earliest stages could dramatically reduce cancer deaths because cancers are usually easier to treat ...

Recent research highlights that for fertility and aging, the egg may be the leading lady, but she needs her supporting cast.

A research team reports a promising new strategy: combining two already-approved drugs—silybin, a natural liver-protective ...